• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·7730.T
Share

Mani, Inc. Stocks

¥ 1684Last Updated 12.06.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

¥ 1.03B

¥ 1684
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Mani, Inc., a company established in Utsunomiya, Japan, in 1956, operates as a prominent player in the global healthcare technology sector. The firm specializes in the research, development, manufacturing, and worldwide distribution of sophisticated medical and dental instruments. Its diverse range of medical offerings includes various surgical tools such as maniplers, vessel knives, general knives, stainless steel wire needles, and saws, which are indispensable for tasks like incision, cutting, and suturing during surgical procedures. For ophthalmic care, the company provides specialized instruments like eye sutures, surgical knives, and trocar kits, essential for intricate eye operations, notably cataract surgeries. Furthermore, Mani, Inc. produces both eyeless and eyed surgical needles. In the dental field, the company delivers a comprehensive assortment of products. This includes a variety of endodontic instruments (both standard and rotary), materials for root canal obturation, diamond and carbide burs, finishing and polishing instruments, dental sutures and surgical needles, as well as specialized micro-accessories and general accessories for endodontics. Beyond its manufacturing activities, Mani, Inc. also engages in the import and distribution of other medical devices.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of 7730.T is 1888 and suggests 12% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.06.2026 16:01

Highlights in small-caps: record IPO in biotech, Wizz Air success, SpaceX effect

13.06.2026 13:01

An investment idea for all times, IPO of the year and how to keep emotions in check in the stock market

13.06.2026 03:02

Microsoft is considering spinning off Xbox into a separate company - The Information

13.06.2026 01:40

Hope for peace with Iran and SpaceX lifted spirits: stocks rose for second straight day

13.06.2026 01:05

SpaceX shares rose in value by 19% on the first day of trading. Is it worth buying them?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026